Establishing a risk stratification model to identify clinically high-risk N0 breast cancer who could benefit from regional nodal irradiation: a single institute analysis

被引:0
|
作者
Qi, Wei-Xiang [1 ,2 ]
Cao, Lu [1 ,2 ]
Ou, Dan [1 ,2 ]
Li, Shuyan [1 ,2 ]
Xu, Cheng [1 ,2 ]
Cai, Rong [1 ,2 ]
Xu, Haoping [1 ,2 ]
Cai, Gang [1 ,2 ]
Chen, Jiayi [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Radiat Oncol, Sch Med, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Key Lab Proton Therapy, Sch Med, Shanghai, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
美国国家科学基金会;
关键词
breast cancer; risk stratification; beast conserving surgery; whole breast irradiation; regional nodal irradiation; INTERNAL MAMMARY; TUMOR LOCATION; FOLLOW-UP; STAGE; MASTECTOMY; RECURRENCE; SURVIVAL; SURGERY; WOMEN;
D O I
10.3389/fonc.2024.1290852
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The purpose of this real-world study was to investigate the risk factors for developing recurrence among patients with pathological T1-3N0 breast cancer (BC) treated with breast-conserving surgery (BCS) followed by whole breast irradiation alone (WBI) and identify those clinically high-risk BCs who could benefit from regional nodal irradiation (RNI). Materials and methods Female BC patients treated at Shanghai Ruijin hospital from 2009 to 2016 were retrospectively reviewed. The disease-free survival (DFS), breast cancer specific survival (BCSS) and overall survival (OS) were estimated by the Kaplan-Meier method, and survival differences were compared with the log-rank test. Univariate and multivariate analysis was performed using Cox proportional hazards regression analysis. An external validation was conducted by using SEER database. Results A total of 622 BC patients treated with BCS+WBI alone were included. With a median follow-up of 82 months, the 7-year OS, BCSS and DFS for the entire cohort was 97%, 99% and 91%, respectively. Multivariable Cox analysis indicated that tumor size (p=0.006), tumor location (p=0.033), lymphovascular invasion (LVI) status (p=0.0028) and Ki-67 index (p=0.051) were independent risk factors for DFS. A scoring system was developed using these four factors and the 7-year DFS and OS were 97% and 96% for patients with 0-1 risk factors, 95% and 82% for patients with >= 2 risk factors (p<0.0001 for DFS, and p=0.0063 for OS). Based on tumor size and tumor location, an external validation by demonstrated that the 7-year OS was 90% and 88% for patients with 0-1 risk factor, which was significantly better than those defined as high-risk BC patients (82%, p<0.0001). Conclusion By using our institute database, we establish a risk stratification system for identifying sub-group of pN0 BC patients, who are at high risk for developing recurrence. The results of our study support tailored RT decision-making according to individual risks, which needed to be confirmed in further studies.
引用
下载
收藏
页数:10
相关论文
共 41 条
  • [21] A 3-Dimensional CT-Based Analysis of Dosimetric Coverage on the Patterns of Locoregional Recurrence in High-Risk Breast Cancer Patients Treated with Regional Nodal Irradiation
    Kim, D. W.
    Petkovska, N.
    Qian, J. M.
    Forman, R.
    Muralidhar, V.
    Mahal, B. A.
    Napolitano, B.
    Naoum, G. E.
    McIntyre, J. F.
    Jimenez, R. B.
    MacDonald, S.
    Preble, R. G.
    Taghian, A. G.
    Ho, A. Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E4 - E4
  • [22] What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
    Maltoni, Roberta
    Bravaccini, Sara
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (01) : 231 - 232
  • [23] What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
    Roberta Maltoni
    Sara Bravaccini
    Breast Cancer Research and Treatment, 2019, 177 : 231 - 232
  • [24] Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?
    Hou, X.
    Yang, M-Z
    Li, J-B
    Tan, Z-H
    Long, H.
    Fu, J-H
    Zhang, L-J
    Lin, P.
    Yang, H-X
    ESMO OPEN, 2022, 7 (03)
  • [25] The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2.
    Mittempergher, Lorenza
    Kuilman, Midas M.
    Barcaru, Andrei
    Nota, Benjamin
    Delahaye, Leonie J. M. J.
    Audeh, M. William
    Wolf, Denise M.
    Yau, Christina
    Swigart, Lamorna Brown
    Hirst, Gillian L.
    Symmans, W. Fraser Fraser
    Lu, Ruixiao
    Liu, Minetta C.
    Nanda, Rita
    Esserman, Laura
    van ' T Veer, Laura
    Glas, Annuska M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Do we need to stage the axilla prior to neo adjuvant chemo? Analysis of clinically and radiologicaly negative (N0) breast cancer patients from a single centre
    Anwer, Abdul
    Salim, Mariam
    Shah, Fahd
    Pirzada, Muhammad
    Nasir, Irfan ul Islam
    Khan, Amina
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : 169 - 170
  • [27] Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer
    Tward, Jonathan David
    Schlomm, Thorsten
    Bardot, Stephen
    Freedland, Stephen J.
    Lenz, Lauren
    Cohen, Todd
    Stone, Steven
    Bishoff, Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1 (n=3424).
    Harbeck, N
    Kates, RE
    Look, MP
    Klijn, JGM
    Schmitt, M
    Foekens, JA
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S30 - S30
  • [29] Responses to induction chemotherapy and high dose melphalan can be incorporated within a risk stratification model and help to identify myeloma patients who may benefit from novel therapies
    Alvares, CL
    Davies, FE
    Horton, C
    Patel, G
    Zuha, R
    Gatt, A
    Saso, R
    Treleaven, J
    Ethell, M
    Potter, M
    Dearden, C
    Morgan, GJ
    BLOOD, 2004, 104 (11) : 658A - 658A
  • [30] Loco-regional recurrence after mastectomy in high-risk breast cancer-risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials
    Nielsen, Hanne M.
    Overgaard, Marie
    Grau, Cai
    Jensen, Anni R.
    Overgaard, Jens
    RADIOTHERAPY AND ONCOLOGY, 2006, 79 (02) : 147 - 155